Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

Restricted access

Hairy cell leukemia (HCL) is a rare type of indolent B-cell leukemia, characterized by symptoms of fatigue and weakness, organomegaly, pancytopenia, and recurrent opportunistic infections. Classic HCL should be considered a distinct clinical entity separate from HCLvariant (HCLv), which is associated with a more aggressive disease course and may not respond to standard HCL therapies. Somatic hypermutation in the IGHV gene is present in most patients with HCL. The BRAF V600E mutation has been reported in most patients with classic HCL but not in those with other B-cell leukemias or lymphomas. Therefore, it is necessary to distinguish HCLv from classic HCL. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of classic HCL.

  • 1.

    Teras LR, DeSantis CE, Cerhan JR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 2016;66:443459.

    • Search Google Scholar
    • Export Citation
  • 2.

    Grever MR, Abdel-Wahab O, Andritsos LA. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood 2017;129:553560.

    • Search Google Scholar
    • Export Citation
  • 3.

    Kraut E. Infectious complications in hairy cell leukemia. Leuk Lymphoma 2011;52(Suppl 2):5052.

  • 4.

    Foucar K, Falini B, Catovsky D, Stein H. Hairy cell leukaemia. In: Swerdlow SH, Campo E, Harris NL, eds. WHO Classification of Tumours or Haematopoietic and Lymphoid Tissues, 4th edition. Lyon, France: IARC Press; 2008:188190.

    • Search Google Scholar
    • Export Citation
  • 5.

    Piris M, Foucar K, Mollejo M. Splenic B-cell lymphoma/leukaemia, unclassifiable. In: Swerdlow SH, Campo E, Harris NL, eds. WHO Classification of Tumours or Haematopoietic and Lymphoid Tissues, 4th edition. Lyon, France: IARC Press; 2008:191193.

    • Search Google Scholar
    • Export Citation
  • 6.

    Arons E, Sunshine J, Suntum T, Kreitman RJ. Somatic hypermutation and VH gene usage in hairy cell leukaemia. Br J Haematol 2006;133:504512.

  • 7.

    Arons E, Roth L, Sapolsky J. Evidence of canonical somatic hypermutation in hairy cell leukemia. Blood 2011;117:48444851.

  • 8.

    Forconi F, Sozzi E, Cencini E. Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. Blood 2009;114:46964702.

    • Search Google Scholar
    • Export Citation
  • 9.

    Boyd EM, Bench AJ, van ‘t Veer MB. High resolution melting analysis for detection of BRAF exon 15 mutations in hairy cell leukaemia and other lymphoid malignancies. Br J Haematol 2011;155:609612.

    • Search Google Scholar
    • Export Citation
  • 10.

    Tiacci E, Trifonov V, Schiavoni G. BRAF mutations in hairy-cell leukemia. N Engl J Med 2011;364:23052315.

  • 11.

    Andrulis M, Penzel R, Weichert W. Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. Am J Surg Pathol 2012;36:17961800.

    • Search Google Scholar
    • Export Citation
  • 12.

    Arcaini L, Zibellini S, Boveri E. The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood 2012;119:188191.

  • 13.

    Xi L, Arons E, Navarro W. Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood 2012;119:33303332.

  • 14.

    Shao H, Calvo KR, Gronborg M. Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria. Leuk Res 2013;37:401409.

    • Search Google Scholar
    • Export Citation
  • 15.

    Robak T. Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment. Cancer Treat Rev 2011;37:310.

  • 16.

    Wang XJ, Kim A, Li S. Immunohistochemical analysis using a BRAF V600E mutation specific antibody is highly sensitive and specific for the diagnosis of hairy cell leukemia. Int J Clin Exp Pathol 2014;7:43234328.

    • Search Google Scholar
    • Export Citation
  • 17.

    Turakhia S, Lanigan C, Hamadeh F. Immunohistochemistry for BRAF V600E in the differential diagnosis of hairy cell leukemia vs other splenic B-cell lymphomas. Am J Clin Pathol 2015;144:8793.

    • Search Google Scholar
    • Export Citation
  • 18.

    Arons E, Suntum T, Stetler-Stevenson M, Kreitman RJ. VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood 2009;114:46874695.

    • Search Google Scholar
    • Export Citation
  • 19.

    Waterfall JJ, Arons E, Walker RL. High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias. Nat Genet 2014;46:810.

    • Search Google Scholar
    • Export Citation
  • 20.

    Kraut EH, Grever MR, Bouroncle BA. Long-term follow-up of patients with hairy cell leukemia after treatment with 2’-deoxycoformycin. Blood 1994;84:40614063.

    • Search Google Scholar
    • Export Citation
  • 21.

    Grever M, Kopecky K, Foucar MK. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an Intergroup study. J Clin Oncol 1995;13:974982.

    • Search Google Scholar
    • Export Citation
  • 22.

    Flinn IW, Kopecky KJ, Foucar MK. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 2000;96:29812986.

    • Search Google Scholar
    • Export Citation
  • 23.

    Johnston JB, Eisenhauer E, Wainman N. Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study. Semin Oncol 2000;27:3236.

    • Search Google Scholar
    • Export Citation
  • 24.

    Maloisel F, Benboubker L, Gardembas M. Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients. Leukemia 2003;17:4551.

    • Search Google Scholar
    • Export Citation
  • 25.

    Else M, Dearden CE, Matutes E. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 2009;145:733740.

    • Search Google Scholar
    • Export Citation
  • 26.

    Dearden CE, Else M, Catovsky D. Long-term results for pentostatin and cladribine treatment of hairy cell leukemia. Leuk Lymphoma 2011;52(Suppl 2):2124.

    • Search Google Scholar
    • Export Citation
  • 27.

    Cheson BD, Sorensen JM, Vena DA. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol 1998;16:30073015.

    • Search Google Scholar
    • Export Citation
  • 28.

    Saven A, Burian C, Koziol JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998;92:19181926.

    • Search Google Scholar
    • Export Citation
  • 29.

    Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 2003;21:891896.

    • Search Google Scholar
    • Export Citation
  • 30.

    Jehn U, Bartl R, Dietzfelbinger H. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia 2004;18:14761481.

    • Search Google Scholar
    • Export Citation
  • 31.

    Zinzani PL, Tani M, Marchi E. Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine. Haematologica 2004;89:309313.

    • Search Google Scholar
    • Export Citation
  • 32.

    Chadha P, Rademaker AW, Mendiratta P. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood 2005;106:241246.

    • Search Google Scholar
    • Export Citation
  • 33.

    Rosenberg JD, Burian C, Waalen J, Saven A. Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series. Blood 2014;123:177183.

    • Search Google Scholar
    • Export Citation
  • 34.

    Juliusson G, Heldal D, Hippe E. Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J Clin Oncol 1995;13:989995.

    • Search Google Scholar
    • Export Citation
  • 35.

    von Rohr A, Schmitz SF, Tichelli A. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study. Ann Oncol 2002;13:16411649.

    • Search Google Scholar
    • Export Citation
  • 36.

    Zenhausern R, Von Rohr A, Rufibach K. Low dose 2-chlorodeoxyadenosine given as a single subcutaneous injection in patients with hairy cell leukemia: a multicentre trial SAKK 32/95. Leuk Lymphoma 2009;50:133136.

    • Search Google Scholar
    • Export Citation
  • 37.

    Forconi F, Cencini E, Zaja F. Analysis of toxicity and efficacy of subcutaneous cladribine at reduced or standard doses (five versus seven consecutive days) in patients with hairy cell leukemia (HCL) in the ICGHCL2004 protocol by the Italian Cooperative Group on HCL [abstract]. Blood 2010;116:Abstract 701.

    • Search Google Scholar
    • Export Citation
  • 38.

    Khorshid O, Namour AE, El-Gammal MM. Efficacy and safety of cladribine: subcutaneous versus intravenous administration in hairy cell leukemia patients. Mediterr J Hematol Infect Dis 2015;7:e2015058.

    • Search Google Scholar
    • Export Citation
  • 39.

    Tallman MS, Hakimian D, Variakojis D. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood 1992;80:22032209.

    • Search Google Scholar
    • Export Citation
  • 40.

    Lauria F, Bocchia M, Marotta G. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications. Haematologica 1999;84:2225.

    • Search Google Scholar
    • Export Citation
  • 41.

    Robak T, Jamroziak K, Gora-Tybor J. Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. Blood 2007;109:36723675.

    • Search Google Scholar
    • Export Citation
  • 42.

    Zenhausern R, Schmitz SF, Solenthaler M. Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98). Leuk Lymphoma 2009;50:15011511.

    • Search Google Scholar
    • Export Citation
  • 43.

    Federico M, Frassoldati A, Lamparelli T. Long-term results of alpha interferon as initial therapy and splenectomy as consolidation therapy in patients with hairy cell leukemia. Final report from the Italian Cooperative Group for HCL. Ann Oncol 1994;5:725731.

    • Search Google Scholar
    • Export Citation
  • 44.

    Damasio EE, Clavio M, Masoudi B. Alpha-interferon as induction and maintenance therapy in hairy cell leukemia: a long-term follow-up analysis. Eur J Haematol 2000;64:4752.

    • Search Google Scholar
    • Export Citation
  • 45.

    Benz R, Siciliano RD, Stussi G, Fehr J. Long-term follow-up of interferon-alpha induction and low-dose maintenance therapy in hairy cell leukemia. Eur J Haematol 2009;82:194200.

    • Search Google Scholar
    • Export Citation
  • 46.

    Chihara D, Kantarjian H, O'Brien S. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. Br J Haematol 2016;174:760766.

    • Search Google Scholar
    • Export Citation
  • 47.

    Else M, Dearden CE, Matutes E. Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence. Leuk Lymphoma 2011;52(Suppl 2):7578.

    • Search Google Scholar
    • Export Citation
  • 48.

    Lauria F, Lenoci M, Annino L. Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia. Haematologica 2001;86:10461050.

    • Search Google Scholar
    • Export Citation
  • 49.

    Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood 2003;102:810813.

    • Search Google Scholar
    • Export Citation
  • 50.

    Thomas DA, O'Brien S, Bueso-Ramos C. Rituximab in relapsed or refractory hairy cell leukemia. Blood 2003;102:39063911.

  • 51.

    Zenhausern R, Simcock M, Gratwohl A. Rituximab in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine (SAKK 31/98). Haematologica 2008;93:14261428.

    • Search Google Scholar
    • Export Citation
  • 52.

    Tiacci E, Park JH, De Carolis L. Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. N Engl J Med 2015;373:17331747.

  • 53.

    Tiacci E, De Carolis L, Zaja F. Vemurafenib plus rituximab in hairy cell leukemia: a promising chemotherapy-free regimen for relapsed or refractory patients [abstract]. Blood 2016;128:Abstract 1214.

    • Search Google Scholar
    • Export Citation
  • 54.

    Dietrich S, Pircher A, Endris V. BRAF inhibition in hairy cell leukemia with low-dose vemurafenib. Blood 2016;127:28472855.

  • 55.

    Jones J, Andritsos L, Kreitman RJ. Efficacy and safety of the Bruton tyrosine kinase inhibitor ibrutinib in patients with hairy cell leukemia: stage 1 results of a phase 2 study [abstract]. Blood 2016;128:Abstract 1215.

    • Search Google Scholar
    • Export Citation
  • 56.

    Tadmor T. Purine analog toxicity in patients with hairy cell leukemia. Leuk Lymphoma 2011;52(Suppl 2):3842.

  • 57.

    Cooley L, Dendle C, Wolf J. Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014. Intern Med J 2014;44:13501363.

    • Search Google Scholar
    • Export Citation
  • 58.

    Saven A, Burian C, Adusumalli J, Koziol JA. Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia. Blood 1999;93:24712477.

    • Search Google Scholar
    • Export Citation
  • 59.

    Di Bisceglie AM, Lok AS, Martin P. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology 2015;61:703711.

    • Search Google Scholar
    • Export Citation
  • 60.

    Huang H, Li X, Zhu J. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. JAMA 2014;312:25212530.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 1 0 0
Full Text Views 2241 1332 68
PDF Downloads 648 428 45
EPUB Downloads 0 0 0